SAN DIEGO, July 10, 2023 (GLOBE NEWSWIRE) -- Johnson Fistel, LLP, a law firm specializing in shareholder rights, has announced the initiation of class action lawsuits on behalf of investors of the following companies. Investors are encouraged to review the deadlines listed and submit their information.
Atlas Lithium Class Action: https://www.johnsonfistel.com/investigations/atlas-lithium
SentinelOne Class Action: https://www.johnsonfistel.com/investigations/sentinelone-inc
DZS Class Action: https://www.johnsonfistel.com/investigations/dzs-inc
NovoCure Class Action: https://www.cognitoforms.com/JohnsonFistel/NovoCureLimited
If you suffered a loss and are interested in learning more about being a lead plaintiff, please contact Jim Baker (jimb@johnsonfistel.com) by email or phone at 619-814-4471. If emailing, please include a phone number.
Atlas Lithium Corporation (NASDAQ: ATLX)
Class Period: March 25, 2022 and May 3, 2023
Lead Plaintiff Deadline: August 1, 2023
This Complaint alleges that, throughout the Class Period, Defendants made materially false and misleading statements regarding the Company’s business, operations, and prospects. Specifically, Defendants made false and/or misleading statements and/or failed to disclose that: (i) the Company overstated the success of its lithium mining and misrepresented the nature of its Brazilian mineral rights; (ii) in connection with these misrepresentations, Atlas Lithium conducted deceptive promotions to artificially inflate the value of the Company’s stock; (iii) the foregoing conduct was designed to allow CEO Fogassa and other Company insiders to sell shares back into the market for a profit before the true nature of Atlas Lithium’s business was revealed; and (iv) as a result, Defendants’ public statements were materially false and/or misleading at all relevant times.
SentinelOne, Inc. (NYSE: S)
Class Period: June 1, 2022 and June 1, 2023
Lead Plaintiff Deadline: August 7, 2023
The SentinelOne class action lawsuit alleges that defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (i) SentinelOne lacked effective internal controls over accounting and financial reporting; (ii) as a result, SentinelOne's Annualized Recurring Revenue ("ARR") was overstated; and (iii) consequently, SentinelOne's guidance was overstated.
DZS Inc. (NASDAQ: DZSI)
Class Period: March 10, 2023 and May 31, 2023
Lead Plaintiff Deadline: August 14, 2023
The lawsuit alleges DZS made materially false and/or misleading statements and/or failed to disclose material adverse facts, including: (1) DZS’ financial statements from March 31, 2023 to the present contained certain errors; (2) as a result, DZS would need to restate its previously filed quarterly financial statement for the period ending March 31, 2023; (3) the Company had ongoing undisclosed issues with its internal controls over financial reporting; and (4) as a result, Defendants’ statements about its business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times.
NovoCure Limited (NASDAQ: NVCR)
Class Period: January 5, 2023 and June 5, 2023
Lead Plaintiff Deadline: August 18, 2023
According to the lawsuit, defendants made false and/or misleading statements regarding the Company’s business, operations, and prospects. Specifically, defendants failed to disclose to investors that: (1) the Company concealed the true nature of the LUNAR study results—that the overwhelmingly positive way that the Company described them was only a half-truth at best given that the study failed to evaluate the efficacy of the drug against a population of patients that had been receiving standard of care treatment; (2) as a result, the Company’s business prospects, effectiveness of its products, and ultimately the likelihood of FDA approval were materially misleading during the Class Period; (3) the foregoing, once revealed, was reasonably likely to have a material negative impact on the Company’s financial condition; and (4) as a result, the Company’s public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.
A lead plaintiff will act on behalf of all other class members in directing the class-action lawsuit. The lead plaintiff can select a law firm of its choice to litigate the class-action lawsuit. An investor's ability to share any potential future recovery of the class action lawsuit is not dependent upon serving as lead plaintiff.
If you suffered a loss and are interested in learning more about being a lead plaintiff, please contact Jim Baker (jimb@johnsonfistel.com) by email or phone at 619-814-4471. If emailing, please include a phone number.
For more information regarding the lead plaintiff process please refer to https://www.johnsonfistel.com/lead-plaintiff-deadlines.
About Johnson Fistel, LLP:
Johnson Fistel, LLP is a nationally recognized shareholder rights law firm with offices in California, New York and Georgia. The firm represents individual and institutional investors in shareholder derivative and securities class action lawsuits. Johnson Fistel seeks to recover losses incurred due to violations of federal securities laws. For more information about the firm and its attorneys, please visit http://www.johnsonfistel.com. Attorney advertising. Past results do not guarantee future outcomes.
Contact:
Johnson Fistel, LLP
Jim Baker, 619-814-4471
Investor Relations
jimb@johnsonfistel.com
